4
Changes in Ownership
Evommune, Inc. Filed Acc 0002092017-26-000009
Options or other derivatives
- Chief Scientific Officer acquired 248,934 shares (grant or award)
- Chief Scientific Officer returned 248,934 shares (to the company)
From the SEC's structured data for this filing
Trades in this filing
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Patel Jeegar Pravinkumar Chief Scientific Officer | 2026-11-13 | Returned to the company · Stock Option (Right to buy) | −179,619 | $16.00 | 2035-11-04 | 179,619 | 0 | D: show line 1 in the form | ||
| Patel Jeegar Pravinkumar Chief Scientific Officer | 2026-11-13 | Grant or award · Stock Option (Right to buy) | +179,619 | $7.63 | 2035-11-04 | 179,619 | 179,619 | D: show line 2 in the form | ||
| Patel Jeegar Pravinkumar Chief Scientific Officer | 2026-11-13 | Returned to the company · Stock Option (Right to buy) | −69,315 | $26.77 | 2036-04-15 | 69,315 | 0 | D: show line 3 in the form | ||
| Patel Jeegar Pravinkumar Chief Scientific Officer | 2026-11-13 | Grant or award · Stock Option (Right to buy) | +69,315 | $7.63 | 2036-04-15 | 69,315 | 69,315 | D: show line 4 in the form |
Loading xslF345X06/primarydocument.xml…